A Case of Rivaroxaban Associated Intracranial Hemorrhage

Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Jean Chin-Yu, Gerona, Roy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Department of Emergency Medicine, University of California, Irvine School of Medicine 2014
Materias:
Diagnostic Acumen
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100836/
https://www.ncbi.nlm.nih.gov/pubmed/25035736
http://dx.doi.org/10.5811/westjem.2014.2.19440
_version_ 1782326721009156096
author Lo, Jean Chin-Yu
Gerona, Roy R.
author_facet Lo, Jean Chin-Yu
Gerona, Roy R.
author_sort Lo, Jean Chin-Yu
collection PubMed
description Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first case reports of severe intracranial hemorrhage associated with rivaroxaban in an elderly patient with decreased renal function. We aim to alert emergency medicine providers regarding the likelihood of encountering these patient as newer anticoagulants rise in popularity.
format Online
Article
Text
id pubmed-4100836
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Department of Emergency Medicine, University of California, Irvine School of Medicine
record_format MEDLINE/PubMed
spelling pubmed-41008362014-07-17 A Case of Rivaroxaban Associated Intracranial Hemorrhage Lo, Jean Chin-Yu Gerona, Roy R. West J Emerg Med Diagnostic Acumen Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first case reports of severe intracranial hemorrhage associated with rivaroxaban in an elderly patient with decreased renal function. We aim to alert emergency medicine providers regarding the likelihood of encountering these patient as newer anticoagulants rise in popularity. Department of Emergency Medicine, University of California, Irvine School of Medicine 2014-07 /pmc/articles/PMC4100836/ /pubmed/25035736 http://dx.doi.org/10.5811/westjem.2014.2.19440 Text en Copyright © 2014 the authors. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Diagnostic Acumen
Lo, Jean Chin-Yu
Gerona, Roy R.
A Case of Rivaroxaban Associated Intracranial Hemorrhage
title A Case of Rivaroxaban Associated Intracranial Hemorrhage
title_full A Case of Rivaroxaban Associated Intracranial Hemorrhage
title_fullStr A Case of Rivaroxaban Associated Intracranial Hemorrhage
title_full_unstemmed A Case of Rivaroxaban Associated Intracranial Hemorrhage
title_short A Case of Rivaroxaban Associated Intracranial Hemorrhage
title_sort case of rivaroxaban associated intracranial hemorrhage
topic Diagnostic Acumen
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100836/
https://www.ncbi.nlm.nih.gov/pubmed/25035736
http://dx.doi.org/10.5811/westjem.2014.2.19440
work_keys_str_mv AT lojeanchinyu acaseofrivaroxabanassociatedintracranialhemorrhage
AT geronaroyr acaseofrivaroxabanassociatedintracranialhemorrhage
AT lojeanchinyu caseofrivaroxabanassociatedintracranialhemorrhage
AT geronaroyr caseofrivaroxabanassociatedintracranialhemorrhage

Ejemplares similares